VICORE PHARMA HOLDING AB ADR
VCRENASDAQ🏆 #3449 by market capUS Equity
$287.43▲ $22.71 (+7.90%)
Simulated priceTrack VCRE
Get earnings, price moves & breaking news on Telegram
24h▲ 7.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$282M
Small Cap
📈Revenue Growth (YoY)
-48.4%
Declining
📊Gross Margin
360.3%
High
💵FCF Margin
—
⚖️P/S Ratio
668.2x
Expensive
Otter Score
52
Weak
No chart data available for VCRE.
Trading Snapshot
- Day Range
- $283.48 – $292.95
- 52-Week Range
- —
- Volume
- $2.45B
- Avg Volume
- $2.12B
- Shares Outstanding
- 281.5M
- Next Earnings
- Nov 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $228,246
- P/E Ratio
- —
- P/S Ratio
- 668.2x
- EPS (TTM)
- —
- Dividend Yield
- —
- Dilution (1yr)
- −88.2%
Why Investors Own VCRE
- ✓High-growth profile — revenue up +3.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 40% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
VICORE PHARMA HOLDING AB ADR
VCREFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4M▼ −96.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$454M▲ +138.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$376M▲ +127.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
25.6M▼ −88.2% YoY
StockOtter · stockotter.spaceAbout VICORE PHARMA HOLDING AB ADR
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100
Analyst Price Target
ⓘAverage Target
$350.63
▲ +22.0% Upside
High Target$428.01
Low Target$278.50
Based on 33 analysts
Latest News & Updates
🚀
Barron’s·2h ago
VICORE PHARMA HOLDING AB ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift VCRE price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
VICORE PHARMA HOLDING AB ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.